Skip to content
Bored Studies
RecruitingPhase 3

BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Braveheart Bio, Inc. · NCT07755904

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–85 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
210
US sites recruiting
3
Study start
September 2, 2026
Record last updated
October 2, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.

Being studied: BHB-1893; Metoprolol

Conditions: Cardiomyopathy, Hypertrophic Obstructive

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Diagnosed with oHCM per the protocol specified criteria
  • NYHA Class II or III at screening visits
  • KCCQ-CSS that meets the protocol specified criteria at screening visits
  • Adequate acoustic windows for echocardiography

Key Exclusion Criteria

  • Medical indication for either β-blocker or calcium-channel blocker therapy, other than oHCM, prohibiting drug discontinuation
  • History of intolerance or medical contraindication to β-blocker therapy
  • Resting systolic blood pressure (SBP) of >160 millimeters of mercury (mmHg) at screening visits
  • Resting heart rate of >100 beats per minute (bpm) at screening visits
  • Significant valvular heart disease, defined as:
  • Moderate to severe valvular aortic stenosis or fixed subaortic obstruction;
  • Mitral regurgitation not due to systolic anterior motion of the mitral valve (per Investigator's judgment)

Other protocol-defined criteria apply.

Recruiting US locations

Study contacts (from the official record)

  • Study Director · (415) 707-6312 · info@braveheart.bio
All heart & blood pressure studies in New York →
BHB-1893 Versus Metoprolol for Symptomatic Obstructive… (NCT07755904) | Bored Studies